Insulin resistance in Alzheimer's disease

Kelly Dineley, Jordan B. Jahrling, Larry Denner

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD.Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD.

Original languageEnglish (US)
Pages (from-to)92-103
Number of pages12
JournalNeurobiology of Disease
Volume72
Issue numberPA
DOIs
StatePublished - Dec 1 2014

Fingerprint

Insulin Resistance
Alzheimer Disease
Insulin
Disease Resistance
Animal Models
Learning
PPAR gamma
Insulin Receptor
Cell Surface Receptors
Cytoplasmic and Nuclear Receptors
Homeostasis
Transcription Factors
Phosphotransferases
Clinical Trials
Hormones
Pathology
Inflammation
Lipids
Glucose
Therapeutics

Keywords

  • Alzheimer's disease
  • Animal models
  • Cognitive function
  • ERK
  • Insulin resistance
  • Learning and memory
  • Metabolism
  • Mitochondria
  • PPAR gamma
  • Therapeutic windows

ASJC Scopus subject areas

  • Neurology

Cite this

Insulin resistance in Alzheimer's disease. / Dineley, Kelly; Jahrling, Jordan B.; Denner, Larry.

In: Neurobiology of Disease, Vol. 72, No. PA, 01.12.2014, p. 92-103.

Research output: Contribution to journalArticle

Dineley, Kelly ; Jahrling, Jordan B. ; Denner, Larry. / Insulin resistance in Alzheimer's disease. In: Neurobiology of Disease. 2014 ; Vol. 72, No. PA. pp. 92-103.
@article{7972f8d6322f47a28f9f9de3da547c56,
title = "Insulin resistance in Alzheimer's disease",
abstract = "Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD.Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD.",
keywords = "Alzheimer's disease, Animal models, Cognitive function, ERK, Insulin resistance, Learning and memory, Metabolism, Mitochondria, PPAR gamma, Therapeutic windows",
author = "Kelly Dineley and Jahrling, {Jordan B.} and Larry Denner",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.nbd.2014.09.001",
language = "English (US)",
volume = "72",
pages = "92--103",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "PA",

}

TY - JOUR

T1 - Insulin resistance in Alzheimer's disease

AU - Dineley, Kelly

AU - Jahrling, Jordan B.

AU - Denner, Larry

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD.Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD.

AB - Insulin is a key hormone regulating metabolism. Insulin binding to cell surface insulin receptors engages many signaling intermediates operating in parallel and in series to control glucose, energy, and lipids while also regulating mitogenesis and development. Perturbations in the function of any of these intermediates, which occur in a variety of diseases, cause reduced sensitivity to insulin and insulin resistance with consequent metabolic dysfunction. Chronic inflammation ensues which exacerbates compromised metabolic homeostasis. Since insulin has a key role in learning and memory as well as directly regulating ERK, a kinase required for the type of learning and memory compromised in early Alzheimer's disease (AD), insulin resistance has been identified as a major risk factor for the onset of AD. Animal models of AD or insulin resistance or both demonstrate that AD pathology and impaired insulin signaling form a reciprocal relationship. Of note are human and animal model studies geared toward improving insulin resistance that have led to the identification of the nuclear receptor and transcription factor, peroxisome proliferator-activated receptor gamma (PPARγ) as an intervention tool for early AD.Strategic targeting of alternate nodes within the insulin signaling network has revealed disease-stage therapeutic windows in animal models that coalesce with previous and ongoing clinical trial approaches. Thus, exploiting the connection between insulin resistance and AD provides powerful opportunities to delineate therapeutic interventions that slow or block the pathogenesis of AD.

KW - Alzheimer's disease

KW - Animal models

KW - Cognitive function

KW - ERK

KW - Insulin resistance

KW - Learning and memory

KW - Metabolism

KW - Mitochondria

KW - PPAR gamma

KW - Therapeutic windows

UR - http://www.scopus.com/inward/record.url?scp=84909606636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909606636&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2014.09.001

DO - 10.1016/j.nbd.2014.09.001

M3 - Article

C2 - 25237037

AN - SCOPUS:84909606636

VL - 72

SP - 92

EP - 103

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - PA

ER -